Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Apr 2013
Randomized Controlled Trial Comparative StudyRandomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
Aminosalicylates are first-choice treatment for mild-to-moderately active ulcerative colitis (UC); however, multi-dosing regimens are inconvenient. ⋯ When combined with mesalazine enema, prolonged-release mesalazine once-daily 4 g is as effective and well tolerated as 2 g twice-daily for inducing remission in patients with mild-to-moderately active ulcerative colitis (Clinicaltrials.gov: NCT00737789).
-
Aliment. Pharmacol. Ther. · Apr 2013
The aspirin cardiovascular/gastrointestinal risk calculator--a tool to aid clinicians in practice.
Assessment of both GI and CV risks vs. the benefits of low-dose aspirin for individual patients can be difficult in clinical practice. ⋯ There are many clinical situations where the number of potential upper GI complications induced by low-dose aspirin may exceed the number of potentially prevented CV events. A risk calculator should guide physicians in choosing appropriate therapy and maximise the aspirin benefit.